Understanding the impact of hypoglycemia on the cardiovascular system

References

• Morrish NJ, Wang SL, Stevents LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetes. 2001;2:S14–S21.
   Google Scholar
• Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48(5):937–942.
   PubMed Web of Science ®Google Scholar
• Schnell O, Cappuccio F, Genovese S, et al. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;28(12):156.
   Google Scholar
• Khunti K, Davies M, Majeed A. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316–322.
   PubMed Web of Science ®Google Scholar
• Cariou B, Fontaine P, Eschwege E. Frequency and predictors of confirmed hypoglycemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metabolism. 2015;41(2):116–125.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Reichard P, Berglund B, Britz A. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med. 1991;230:101–108.
   PubMed Web of Science ®Google Scholar
• MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med. 1993;10:238–245.
   PubMed Web of Science ®Google Scholar
• Khunti K, Alsifri S, Aronson R. Rates and predictors of hypoglycaemia in 27585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metabolism. 2016;18(9):907–915.
   PubMed Web of Science ®Google Scholar
• Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes (2005). Diabetes Care. 2005;28,:1568–1573.
   PubMed Web of Science ®Google Scholar
• UK hypoglycemia Study Group. Rise of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147.
   PubMed Web of Science ®Google Scholar
• Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–1912.
   PubMed Web of Science ®Google Scholar
• Brady PA, Terzic AJ. The sulfonylurea controversy: more questions from the heart. Am Coll Cardiol. 1998 Apr;31(5):950–956.
   PubMed Web of Science ®Google Scholar
• Williams SA, Shi L, Brenneman SK. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012;26(5):399–406.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418.
   PubMed Web of Science ®Google Scholar
• McCoy RG, Van Houten HK, Ziegenfuss JY. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012 Sep;35(9):1897–1901. DOI:10.2337/dc11-2054
   PubMed Web of Science ®Google Scholar
• Benson JW Jr, Johnson DG, Palmer JP. Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man. J Clin Endocrinol Metab. 1977 Mar;44(3):459–464.
   PubMed Web of Science ®Google Scholar
• Amiel SA, Simonson DC, Tamborlane WV. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans. Diabetes. 1987 Apr;36(4):518–522.
   PubMed Web of Science ®Google Scholar
• Keen H. The diabetes control and complications trial (DCCT). Health Trends. 1994;26:41–43.
   PubMedGoogle Scholar
• Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353–363.
   PubMed Web of Science ®Google Scholar
• Petersen KG, Schluter KJ, Kerp L. Regulation of serum potassium during insulin-induced hypoglycemia. Diabetes. 1982;31(7):615–617.
   PubMed Web of Science ®Google Scholar
• Heller SR, Robinson RT. Hypoglycaemia and associated hypokalaemia in diabetes: mechanisms, clinical implications and prevention. Diabetes Obes Metab. 2000;2(2):75–82.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2 receptor stimulation by circulating adrenaline. N Engl J Med. 1983;309:1414–1419.
   PubMed Web of Science ®Google Scholar
• Reno CM, Daphna-Iken D, Chen YS, et al. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes. 2013;62:3570–3581.
   PubMed Web of Science ®Google Scholar
• Laitinen T, Lyyra-Laitinen T, Huopio H, et al. Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects. Ann Noninvasive Electrocardiol. 2008;13:97–105.
   PubMed Web of Science ®Google Scholar
• Gill GV, Woodward A, Casson IF, et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes: the ‘dead in bed’ syndrome revisited. Diabetologia. 2009;52:42–45.
   PubMed Web of Science ®Google Scholar
• Robinson RT, Harris ND, Ireland RH, et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003;52:1469–1474.
   PubMed Web of Science ®Google Scholar
• Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327–329.
   PubMed Web of Science ®Google Scholar
• Hii JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsades de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation. 1986;86:1376–1382.
   Google Scholar
• Buja J, Miorelli M, Turrini P, et al. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol. 1993;72:973–976.
   PubMed Web of Science ®Google Scholar
• Higham PD, Furniss SS, Campbell RWF. QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J. 1995;73:32–36.
   PubMedGoogle Scholar
• Gruden G, Giunti S, Barutta F, et al. QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012;35(1):125–127.
   PubMed Web of Science ®Google Scholar
• Christensen TF, Tarnow L, Randlov J, et al. QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia. 2010;53(9):2036–2041.
   PubMed Web of Science ®Google Scholar
• Davis SN, Shavers C, Collins L. Effects of physiological hyperinsulinemia on counterregulatory response to prolonged hypoglycemia in normal humans. Am J Physiol. 1994 Sep;267(3 Pt 1):E402–E410.
   PubMedGoogle Scholar
• Wright RJ, Newby DE, Stirling D, et al. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010;33(7):1591–1597.
   PubMed Web of Science ®Google Scholar
• Gogitidze Joy N, Hedrington MS, Briscoe VJ, et al. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010;33(7):1529–1535.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Novials A, Ortega E, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012;61(11):2993–2997.
   PubMed Web of Science ®Google Scholar
• Galloway PJ, Thomson GA, Fisher BM, et al. Insulin-induced hypoglycemia induces a rise in C-reactive protein. Diabetes Care. 2000;23:861–862.
   PubMed Web of Science ®Google Scholar
• Razavi Nematollahi L, Kitabchi AE, Kitabchi AE, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009;58:443–448.
   PubMed Web of Science ®Google Scholar
• Joy NG, Tate DB, Younk LM, et al. Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes. 2015;64:2571–2580.
   PubMed Web of Science ®Google Scholar
• Giménez M, Gilabert R, Monteagudo J, et al. Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care. 2011;34:198–203.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Novials A, Ortega E. Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutr Metab Cardiovasc Dis. 2014 Feb;24(2):116–123. DOI:10.1016/j.numecd.2013.05.003
   PubMed Web of Science ®Google Scholar
• O’Reilly M, O’Sullivan EP, Davenport C, et al. “Dead in bed”: a tragic complication of type 1 diabetes mellitus. Ir J Med Sci. 2010;179(4):585–587.
   PubMed Web of Science ®Google Scholar
• Rothenbuhler A, Bibal CP, Le Fur S, et al. Effects of a controlled hypoglycaemia test on QTc in adolescents with type 1 diabetes. Diabet Med. 2008;25(12):1483–1485.
   PubMed Web of Science ®Google Scholar
• Emily T, Richard B, Johan D, et al. Post-mortem pathologic and genetic studies in “dead in bed syndrome” cases in type 1 diabetes mellitus. Hum Pathol. 2010;41(3):392–400.
   PubMed Web of Science ®Google Scholar
• Skinner JR, Marquis-Nicholson R, Luangpraseuth A. Diabetic dead-in-bed syndrome: a possible link to a cardiac ion channelopathy. Case Rep Med. 2014;2014:647252.
   PubMedGoogle Scholar
• Nathan DM, Bayless M, Cleary P, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: advances and contributions. Diabetes. 2013;62:3976–3986.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
   PubMed Web of Science ®Google Scholar
• Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313(1):45–53.
   PubMed Web of Science ®Google Scholar
• Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification on type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes. 2006;55:3556–3565.
   PubMed Web of Science ®Google Scholar
• Farhmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract. 2015;107(2):280–289.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877–890.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352.9131:837–853.
   Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
   PubMed Web of Science ®Google Scholar
• Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122(8):844–846.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Saremi A, Bahn GD, Reaven PD. A link between hypoglycemia and progression of atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2016 Jan 19;39:448–454. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hayward RA, Reaven PD, Emanuele NV. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(10):978.
   PubMedGoogle Scholar
• Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328.
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Rydén L, Riddle MC, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34(40):3137–3144.
   PubMed Web of Science ®Google Scholar
• Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367(12):1108–1118.
   PubMed Web of Science ®Google Scholar
• Bedenis R, Price AH, Robertson CM, et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(12):3301–3308.
   PubMed Web of Science ®Google Scholar
• Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013 Jul 29;347:f4533. DOI:10.1136/bmj.f4533
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580–591. DOI:10.1056/NEJMoa0706245
   PubMed Web of Science ®Google Scholar
• Rubin RR, Gaussoin SA, Peyrot M. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010 Aug;53(8):1581–1589. Epub 2010 Apr 28. DOI:10.1007/s00125-010-1765-1.
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010 Jan 8;340:b5444. DOI:10.1136/bmj.b5444
   PubMed Web of Science ®Google Scholar
• Mitrakou A, Ryan C, Veneman T. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991 Jan;260(1 Pt 1):E67–E74.
   PubMedGoogle Scholar
• Litvin M, Clark AL, Fisher SJ. Recurrent hypoglycemia: boosting the brain’s metabolic flexibility. J Clin Invest. 2013;123(5):1922–1924.
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010 Jun;33(6):1389–1394. DOI:10.2337/dc09-2082
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12;295(14):1681–1687.
   PubMed Web of Science ®Google Scholar
• Torimoto K, Okada Y, Mori H. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013 Jan;2(12):1. DOI:10.1186/1475-2840-12-1
   Web of Science ®Google Scholar
• Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014 Oct 13;15(10):18381–18406. DOI:10.3390/ijms151018381
   PubMed Web of Science ®Google Scholar
• Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 1991;84:1516–1523.
   PubMed Web of Science ®Google Scholar
• DeVries JH. Glucose variability: where it is important and how to measure it diabetes. Diabetes. 2013 May;62(5):1405–1408.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128. Epub 2015 Sep 17. DOI:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016 Jan 26;37:1526–1534. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Marso S, Daniels G, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375: 311–322. DOI:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Grabman J, Vajda Bailey K, Schmidt K. An empirically derived short form of the hypoglycaemia fear survey II. Diabet Med. 2016 Jun 9. DOI:10.1111/dme.13162
   PubMedGoogle Scholar
• Bordier L, Buysschaert M, Bauduceau B. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: contributions of the GERODIAB study. Diabetes Metab. 2015;41(4):301–303. DOI:10.1016/j.diabet.2015.03.001
   PubMed Web of Science ®Google Scholar